Pfizer/BioNTech , Says Booster Dose Is , 95.6% Effective in Phase 3 Trial.<br />On October 21, Pfizer/BioNTech said that a booster dose of their coronavirus vaccine was found to have a <br />high efficacy rate in a Phase 3 trial.<br />Pfizer/BioNTech said that <br />a booster dose was 95.6% effective, "irrespective of age, sex, race, <br />ethnicity or comorbid conditions.".<br />CNN reports that the trial included over <br />10,000 fully-vaccinated people ages 16 and older.<br />They randomly received either a 30-microgram booster dose of vaccine or a placebo.<br />Pfizer and BioNTech noted that the results showed <br />a reduction of disease among those who <br />had a booster shot versus those who did not.<br />The companies pointed out that these <br />are the first results from a randomized, <br />controlled COVID-19 vaccine booster trial.<br />These results provide further evidence <br />of the benefits of boosters <br />as we aim to keep people <br />well-protected against this disease. , Albert Bourla, Pfizer Chairman and CEO, via CNN.<br />In addition to our efforts to increase global <br />access and uptake among the unvaccinated, <br />we believe boosters have a critical role <br />to play in addressing the ongoing public <br />health threat of this pandemic, Albert Bourla, Pfizer Chairman and CEO, via CNN.<br />In addition to our efforts to increase global <br />access and uptake among the unvaccinated, <br />we believe boosters have a critical role <br />to play in addressing the ongoing public <br />health threat of this pandemic, Albert Bourla, Pfizer Chairman and CEO, via CNN.<br />We look forward to sharing these <br />data with health authorities and <br />working together to determine <br />how they can be used to support <br />the rollout of booster doses <br />around the world, Albert Bourla, Pfizer Chairman and CEO, via CNN
